齐拉西酮对伴发抑郁症状精神分裂症的临床研究  

A clinical study of ziprasidone in the treatment of schizophrenia with depressive symptoms

作　　者：穆朝娟[1] 李翠鸾[1] 杨丽敏[1] 刘兰芬[1] 

机构地区：[1]山东省精神卫生中心,济南250014

出　　处：《精神医学杂志》2012年第1期29-32,共4页Journal of Psychiatry

摘　　要：目的探讨齐拉西酮对伴发抑郁症状精神分裂症患者的疗效及安全性。方法将98例符合入组条件的精神分裂症患者随机分为齐拉西酮组(30例)、利培酮组(35例)、奋乃静组(33例),疗程8周。分别于治疗前、治疗2周末、4周末、8周末采用阳性和阴性症状量表(PANSS)、卡尔加里精神分裂症抑郁量表(CDSS)评定疗效,用治疗时副反应量表(TESS)评定安全性。结果在治疗8周末时三组PANSS评分、CDSS评分均有显著改善,齐拉西酮组与利培酮组比较无显著性差异,两组均低于奋乃静组(P<0.05);治疗2周末齐拉西酮组CDSS评分较利培酮组显著改善,差异有显著性(P<0.05);治疗4周末、8周末两组疗效相当,各时间点两组CDSS评分与奋乃静组差异有显著性(P<0.05)。齐拉西酮组和利培酮组副作用均较少,低于奋乃静组。结论齐拉西酮与利培酮治疗精神分裂症疗效相当,在阴性症状及伴随的抑郁症状方面改善均优于奋乃静,齐拉西酮在改善抑郁症状时起效更快,安全性更高。Objective To explore the clinical efficacy of ziprasidone in the treatment of schizophrenia complicated with depressive symptoms. Methods A total of 98 schizophrenic patients were randomly divided into ziprasidone group （ n = 30 ）, risperidone group （ n = 35 ）, perphenazine group （ n = 33 ） treated with ziprasidone, risperidone and perphenazine respectively for 8 weeks. Clinical efficacy was assessed with Positive and Negative Sydrome Scale （PANSS）, Calgary Depression Scale for Schizophrenia （CDSS） and side effects was assessed with the Treatment Emergent Symptom Scale （TESS） at the baseline and at the 2nd,4th and 8th weekend of the treatment. Results At the end of the treatment, total score of PANSS and CDSS in three groups decreased significantly compared with the baseline. There were no significant differences in score of PANSS and CDSS between ziprasidone group and risperidone group, but scores of PANSS and CDSS in the two groups were significantly higher than those in perphenazine group （P 〈 0.05）. At the end of the 2nd week, total score of CDSS in ziprasidone group was significantly lower than that in risperidone group （P 〈 0.05）. At the 4th and 8th weekend of the treatment, efficacy in ziprasidone group was almost equal to risperidone group, and there was significant difference in socre of CDSS when compared with perphenazine group （P 〈 0.05 ）. Side effects in ziprasidone group and risperidone group were all mild and were significantly less than that in perphenazine group. Conclusion The efficacy of ziprasidone is equivalent to risperidone in the treatment of schizophrenia. The two agents improves negative symptoms and depressive symptoms more significantly than perphenazine. Ziprasidone takes effect more quickly and has better safety for the improvement of depressive symptoms.

关 键 词：精神分裂症 抑郁症状 齐拉西酮 利培酮奋乃静 

分 类 号：R749.3[医药卫生—神经病学与精神病学]